The APSM has launched a White Paper which attributes an economic value to the provision of unlicensed medicines within the NHS.
The Paper takes a series of typical patient scenarios where a Special is indicated and then identifies the potential cost to the NHS of attempting to meet patient need with a lower cost, higher risk alternative such as tablet crushing.
The White Paper was commissioned in the light of growing concern about cost pressures leading to higher risk practice in the supply chain.
There is regulation and guidance to prevent unnecessary prescribing of a Special and as an industry we have a duty to support this. However, when a Special is indicated, Specials should be manufactured in an MHRA-approved facility wherever possible.
You can read the APSM's White Paper here